Literature DB >> 21498389

Oral vaccines against cholera.

Sunheang Shin1, Sachin N Desai, Binod K Sah, John D Clemens.   

Abstract

The current seventh pandemic of cholera, caused by serogroup O1, El Tor biotype, has now involved almost the entire developing world. The ongoing dynamic epidemiology of cholera, involving evolution of new strains, prolonged and more frequent epidemics, increased antimicrobial resistance, and awareness of the role of climate change upon the global burden has returned cholera to the forefront of global public health discussions. Improved water and sanitation should continue to be the mainstays of cholera-prevention efforts, but major improvements are a far-off goal for much of the cholera-affected developing world. The advent of safe and effective, new-generation oral vaccines against cholera has created renewed interest in the use of vaccines as a tool to control cholera.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21498389     DOI: 10.1093/cid/cir141

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  24 in total

1.  Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh.

Authors:  Daniel T Leung; Mohammad Arif Rahman; M Mohasin; Sweta M Patel; Amena Aktar; Farhana Khanam; Taher Uddin; M Asrafuzzaman Riyadh; Amit Saha; Mohammad Murshid Alam; Fahima Chowdhury; Ashraful Islam Khan; Richelle Charles; Regina LaRocque; Jason B Harris; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

Review 2.  New-generation vaccines against cholera.

Authors:  John Clemens; Sunheang Shin; Dipika Sur; G Balakrish Nair; Jan Holmgren
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-08       Impact factor: 46.802

Review 3.  Vaccines in the time of cholera.

Authors:  John D Clemens
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-11       Impact factor: 11.205

4.  Insights from natural infection-derived immunity to cholera instruct vaccine efforts.

Authors:  Marcela F Pasetti; Myron M Levine
Journal:  Clin Vaccine Immunol       Date:  2012-09-19

Review 5.  Recent progress in mucosal vaccine development: potential and limitations.

Authors:  Nils Lycke
Journal:  Nat Rev Immunol       Date:  2012-07-25       Impact factor: 53.106

6.  Guinea pig complement potently measures vibriocidal activity of human antibodies in response to cholera vaccines.

Authors:  Kyoung Whun Kim; Soyoung Jeong; Ki Bum Ahn; Jae Seung Yang; Cheol-Heui Yun; Seung Hyun Han
Journal:  J Microbiol       Date:  2017-12-07       Impact factor: 3.422

7.  Lipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen.

Authors:  Deborah R Leitner; Sandra Feichter; Kristina Schild-Prüfert; Gerald N Rechberger; Joachim Reidl; Stefan Schild
Journal:  Infect Immun       Date:  2013-04-29       Impact factor: 3.441

8.  Cholera outbreak in districts around Lake Chilwa, Malawi: lessons learned.

Authors:  Amin Khonje; Carol Ann Metcalf; Emma Diggle; Dudley Mlozowa; Chandiwira Jere; Ann Akesson; Tom Corbet; Zachariah Chimanga
Journal:  Malawi Med J       Date:  2012-06       Impact factor: 0.875

9.  Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh.

Authors:  Daniel T Leung; Taher Uddin; Peng Xu; Amena Aktar; Russell A Johnson; Mohammad Arif Rahman; Mohammad Murshid Alam; Meagan Kelly Bufano; Grace Eckhoff; Ying Wu-Freeman; Yanan Yu; Tania Sultana; Farhana Khanam; Amit Saha; Fahima Chowdhury; Ashraf I Khan; Richelle C Charles; Regina C Larocque; Jason B Harris; Stephen B Calderwood; Pavol Kovác; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2013-03-20

10.  Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice.

Authors:  A A Tarique; A Kalsy; M Arifuzzaman; S M Rollins; R C Charles; D T Leung; J B Harris; R C Larocque; A Sheikh; M S Bhuiyan; R Saksena; J D Clements; S B Calderwood; F Qadri; P Kovác; E T Ryan
Journal:  Clin Vaccine Immunol       Date:  2012-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.